Drug Profile
Research programme: interferon-beta stimulant - InDex Pharmaceuticals
Alternative Names: DIMS 9054; IDX-9054Latest Information Update: 25 Nov 2022
Price :
$50
*
At a glance
- Originator InDex Pharmaceuticals
- Class Anti-inflammatories; Oligonucleotides
- Mechanism of Action Interferon beta stimulants; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
- No development reported Multiple sclerosis; Pneumonia
Most Recent Events
- 25 Nov 2022 Preclinical development is still ongoing for Inflammation in Sweden (Parenteral) (Index Pharmaceuticals pipeline, November 2022)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Inflammation in Sweden (Parenteral)
- 28 Feb 2019 No recent reports of development identified for preclinical development in Pneumonia in Sweden (Parenteral)